Milnacipran
- Generic Name
- Milnacipran
- Brand Names
- Savella
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22N2O
- CAS Number
- 92623-85-3
- Unique Ingredient Identifier
- G56VK1HF36
- Background
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression . Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional ...
- Indication
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above .
...
- Associated Conditions
- Fibromyalgia
- Associated Therapies
- -
NDA Filed for TNX-102 SL in Fibromyalgia
Tonix Pharmaceuticals filed an NDA for TNX-102 SL in fibromyalgia, supported by positive Phase 3 trial results. TNX-801, a vaccine for mpox and smallpox, is in development, with new data showing no spread in immunocompromised animals. Tonix is also developing TNX-1500, a third-generation anti-CD40L antibody for autoimmune diseases and transplant rejection. Financial results show decreased R&D and G&A expenses, with $28.2 million in cash and cash equivalents as of September 30, 2024.
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application
Tonix Pharmaceuticals submitted an NDA to the FDA for TNX-102 SL, a non-opioid analgesic for fibromyalgia, based on two successful Phase 3 studies showing significant pain reduction. The drug targets non-restorative sleep and has Fast Track designation, potentially expediting review. If approved, it would be the first new fibromyalgia drug in over 15 years.
Tonix Pharmaceuticals Announces Submission of the TNX-102
Tonix Pharmaceuticals submits NDA for TNX-102 SL, a non-opioid, centrally-acting analgesic for fibromyalgia, after two Phase 3 studies showed significant pain reduction. If approved, TNX-102 SL would be the first new drug for fibromyalgia in over 15 years.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath